Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03413319 | Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 | PHASE1 | COMPLETED | 3 | — | — | Apr 17, 2018 | Nov 20, 2019 | Dec 3, 2019 | 2 | United States |
Adverse events and serious adverse events will be monitored throughout the dosing period and for approximately 20 weeks after the last dose.
| Arm | Type | Description |
|---|---|---|
| ABBV-8E12 | EXPERIMENTAL | ABBV-8E12 administered by intravenous (IV) infusion. |
| Name | Type | Description |
|---|---|---|
| ABBV-8E12 | DRUG | Solution for infusion |
Inclusion Criteria: * Subject completed Study C2N-8E12-WW-104 (NCT02494024) * Subject was not eligible to enroll in Study M15-562 (NCT02985879) Exclusion Criteria: * Subject weighs less than 35 kg at screening * Subject has any contraindication or inability to tolerate brain MRI * Subject has any...